China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2011, sales on the Chinese drug market have reached RMB 1550 billion (about US$246 billion). China is expected to become the second largest drug market in the world by 2015 with a growth rate over 25 percent per annum in next three years. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door to a lucrative drug market for overseas pharmaceutical companies, which attracts more and more overseas pharmaceutical manufacturers and producers to enter such drug market and seize a larger part of such drug market. However, the Chinese social environment for the protection of intellectual property right is complex. The locally produced generics and copy products dominate the Chinese drug market. It is estimated that about 97 percent of the drugs produced by local companies are generics or counterfeits.
Facing such complex social environment and market, most overseas and multinational pharmaceutical companies fear that their imported drugs and pharmaceuticals produced in China will be imitated or copied, in turn, their intellectual property will be infringed and benefit will be violated. What reason incurred such fear of overseas and multinational pharmaceutical companies? Why did Eli Lilly & Company fail in its litigation of patent infringement dispute case inChina? Why can Pfizer win in an administrative proceeding against the Patent Reexamination Board of the China State Intellectual Property Office (SIPO) for its Viagra patent? Lack of knowledge of the Chinese intellectual property right system and legislation institution, the cultural difference between China and Western countries as well as the language barriers incurred such result.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual property in China. This guidebook, targeting overseas and multinational pharmaceutical companies and combining case studies of patent infringement dispute in China from them, will provide a comprehensive and thorough knowledge of the Chinese patent system and legislation institution to guide overseas and multinational pharmaceutical companies step by step to achieve a successful patent protection for their intellectual property in China, which is beginning from the organization structure and the responsibility of Chinese patent authorities, the application for patent, the examination and approval of application for patent, the protection of patent right, to design for compositions of optimized patent protection strategies. Its audiences are the executives from overseas and multinational pharmaceutical companies who have the preliminary knowledge of patent. It is also a textbook for the readers studying in the patent protection for intellectual property rights relating to pharmaceuticals. After having skimmed through this guidebook, audiences and readers can not only be clearly aware of the Chinese patent system and legislation institution, but also design an optimized patent protection strategy for themselves to acquire an adequate protection for their patent right in China.
China’s Guidebook for Pharmaceutical Patent Protection provides a comprehensive and thorough knowledge of the Chinese patent system relating to pharmaceuticals, the detailed administrative, civil and criminal judicial pathways for protections of patent right, and the design for composition of optimized protection strategies.
Who should buy this report?
SIMILAR MARKET STUDIES
Summary Cerner Corporation (Cerner) is a provider of healthcare information technology and related services. It offers a comprehensive range of solutions and services which assist the clinical, financial and operational needs of organizations. The company’s major solutions include extended care solutions; hospitals and health systems solutions; CareAware solutions for medical devices; ...
October 2016 | $250 | View Details >>
The North America Hyaluronic Acid Industry 2015 Deep Market Research Report is a professional and in-depth study on the current state of the Hyaluronic Acid industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Hyaluronic Acid market analysis is provided for ...
December 2015 | $3800 | View Details >>
Notes: Sales, means the sales volume of Oropharyngeal Airways Revenue, means the sales value of Oropharyngeal Airways This report studies sales (consumption) of Oropharyngeal Airways in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering Teleflex Medical ...
November 2016 | $3800 | View Details >>
Summary The Westaim Corporation (Westaim) is a financial service provider. The organization provides long-term capital to businesses operating primarily within the global financial services industry. It invests through acquisitions, joint ventures and other arrangements. The organization invests in various business sectors and partners with other companies. It is a subsidiary of ...
October 2014 | $300 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research